REFERENCES
1. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967;41:1271-4.
2. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Hertz MI, Transplantation International Society of Heart and Lung. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. J Heart Lung Transplant 2012;31:1052-64.
3. Caves PK, Stinson EB, Billingham M, Shumway NE. Percutaneous transvenous endomyocardial biopsy in human heart recipients. Ann Thorac Surg 1973;16:325-36.
4. Billingham ME. Endomyocardial biopsy detection of acute rejection in cardiac allograft recipients. Heart Vessels Suppl 1985;1:86-90.
5. NHS. Organ donation and transplantation- activity (1)s for the UK as at April 2017. NHS blood ant transplantation activity 2017. Available from: https://www.organdonation.nhs.uk/supporting-my-decision/statistics-about-organ-donation/transplant-activity-report/. [Last accessed on 12 Sep 2018].
6. NHS. Annual report on cardiothoracic transplantation. NHS Blood ant Transplantation Activity 2015. Available from: https://www.organdonation.nhs.uk/supporting-my-decision/statistics-about-organ-donation/transplant-activity-report/. [Last accessed on 12 Sep 2018].
7. Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC. Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med 2014;4:pii: a015636.
8. Ayala Garcia MA, Gonzalez Yebra B, Lopez Flores AL, Guani Guerra E. The major histocompatibility complex in transplantation. J Transplant 2012;2012:842141.
9. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR, Kim SK. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006;443:345-9.
12. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Chambers DC, Yusen RD, Stehlik J, Transplantation International Society for Heart and Lung. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourthadult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017;36:1037-46.
13. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL 2nd, Kobashigawa J. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 2004;110:3858-65.
14. Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol 2011;33:157-67.
15. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993;685:400-7.
17. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J, Guidelines International Society of Heart and Lung Transplantation. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-56.
18. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998;66:507-15.
19. Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN, Richardson M, Williams TJ. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002;21:540-6.
20. Colombo D, Ammirati E. Cyclosporine in transplantation - a history of converging timelines. J Biol Regul Homeost Agents 2011;25:493-504.
21. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, Smith A, Valantine H, Ventura H, Mehra M, Vachiery JL, Rayburn BK, Canver CC, Laufer G, Costanzo MR, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C, Masters R, Michaud JL, Paradis I, Renlund DG, Vanhaecke J, Mellein B, Mueller EA. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation. Transplantation 2001;71:70-8.
22. Watson CJ, Dark JH. Organ transplantation: historical perspective and current practice. Br J Anaesth 2012;108 Suppl 1:i29-42.
24. Meiser BM, Groetzner J, Kaczmarek I, Landwehr P, Müller M, Jung S, Uberfuhr P, Fraunberger P, Stempfle HU, Weis M, Reichart B. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004;78:591-8.
25. Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, Marrone GC, Todo S, Fung J, Starzl TE. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc 1991;23:1149-52.
26. Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009;2009:701464.
27. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. WHO: Geneva, Switzerland 2006 .
28. Excellence NIfHaC NI. Type 2 diabetes: prevention in people at high risk. NICE guideline (PH38), 2012.
29. Sharif A, Cohney S. Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol 2016;4:337-49.
30. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 2011;4:175-86.
31. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC, Panel International Expert. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003;75:SS3-24.
32. Velleca A, Kittleson M, Patel J, Rafiei M, Osborne A, Ngan A, Hage A, Chang DH, Czer L, Kobashigawa J. Tacrolimus-versus cyclosporine-induced diabetes leads to more diabetic complications after heart transplantation. J Heart Lung Transplant 2013;32:S202.
33. Reichart B, Meiser B, Viganò M, Rinaldi M, Yacoub M, Banner NR, Gandjbakhch I, Dorent R, Hetzer R, Hummel M. European multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant 2001;20:249-50.
34. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, Tolman DE, Frazier OH, Young JB, VanVeldhuisen P. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressiveregimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999;18:336-45.
35. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R; the Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;1377:86.
36. Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. Transplantation 2013;95:629-34.
37. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75.
38. Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizón Del Prado JM, Pulpón LA, Villemot JP, Frigerio M, Rodriguez Lambert JL, Crespo-Leiro MG, Almenar L, Duveau D, Ordonez-Fernandez A, Gandjbakhch J, Maccherini M, Laufer G. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. Am J Transplant 2006;6:1387-97.
39. Teebken OE, Strüber M, Harringer W, Pichlmaier MA, Haverich A. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in hearttransplant recipients. Transplant Proc 2002;34:1265-8.
40. Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 2000;17:15-9.
41. Baran DA, Ashkar J, Galin ID, Sandler D, Segura L, Courtney MC, Correa R, Chan M, Lansman SL, Spielvogel D, Cheng J, Gass AL. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. Transplant Proc 2002;34:1711-2.
42. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995;60:451-7.
43. Prada-Delgado O, Estevez-Loureiro R, Paniagua-Martin MJ, Lopez-Sainz A, Crespo-Leiro MG. Prevalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature. J Heart Lung Transplant 2012;31:332-3.
44. Kato T, Chan MC, Gao SZ, Schroeder JS, Yokota M, Murohara T, Iwase M, Noda A, Hunt SA, Valantine HA. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 2004;43:1034-41.
45. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010;33:442-9.
